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Abstract
In this study 15 banked samples of HIV-related Non-Hodgkin’s Lymphoma (NHL) cases were tested for HIV co-
receptor usage and SDF1 3’A polymorphism. Reportable tropism from 9 plasma samples had 1 (11.1%) HIV case
with CXCR4 and 8 (88.9%) with CCR5 usage, even though most of the cases occurred at a late stage of HIV (2/3
had CD4 counts below 200), where expected CXCR4 usage would be 60%. Based on the expected proportion of
less than 50% CCR5 in chronically infected individuals, this would suggest that in NHL may be associated with
CCR5 usage (P = 0.04).
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Introduction
Highly active antiretroviral treatment (HAART) has pro-
longed survival in HIV infected individuals [1], however,
HIV associated malignancies remain relatively common
[2]. Lymphoma is a frequent HIV-related malignancy
[3], that generally presents in late HIV disease, possibly
related to worsening immune function that allows latent
Epstein Barr Virus (EBV) in memory B cells to generate
a proliferative condition [4,5]. We considered what HIV
factors may also play a role in lymphoma and noted
that with later HIV disease stages the virus acquires
CXCR4 co-receptor usage [6]. In early stage HIV infec-
tion, at most, only about 15% are dual/mixed (DM) tro-
pic for CCR5 and CXCR4 [7,8], then in late disease
stages, DM tropism or pure CXCR4 tropism reaches up
to 60% when measured by the enhanced tropism assay
[9], and is the highest with CD4 ≤ 200 cells/ml [10,11].
The chemokine receptor CXCR4 is also highly expressed
in hematological malignancies [12,13]. The chemokine
for CXCR4, stromal cell derived factor 1 (SDF1), has
also been associated with HIV associated Non-Hodgkin’s
lymphoma (NHL) when individuals have a polymorph-
ism in the SDF1 gene from G to A transition at position
801 (SDF1-3’A) that increased with homozygosity [14].
In North America, SDF1-3’A is expected in 21% of
Caucasians [15]. Although there was some suggestion
that SDF1-3’A is associated with HIV disease progres-
sion [16], and CXCR4 tropic virus [17]. Based on these
observations, we examined whether HIV co-receptor
u s a g ea n dt h eS D F 1p o l y m o r p h i s m sw e r ea s s o c i a t e d
with HIV-related NHL.
Methods
A study protocol was submitted and approved to the
AIDS and Cancer Specimen Resource (ACSR) to supply
16 samples of NHL from HIV-infected individuals that
had plasma and PBMC samples at a time of viral load
greater than 1000, the threshold required for the Trofile
assay (Monogram Biosciences Inc.). An IRB approval was
obtained to collect and test these samples with diagnosis,
demographics, HIV viral load, CD4 count for each sub-
ject. Samples were shipped from two ACSR repositories
on dry ice and were processed for plasma to be sent for
Trofile ES assay. The PBMCs were processed at the
UCSD Center for AIDS Research Genomics Core labora-
tory. SDF1 polymorphisms were done with SNP analysis
for the SDF 1-3’A polymorphism (Applied Biosystems).
Data analysis employed SAS v 9.2 statistical software to
describe the frequencies of HIV co-receptor tropism,
SDF1-3’A, demographics, CD4 counts and HIV viral
loads at time of the samples. Rates of expected propor-
tions were compared with in a one-sample binomial pro-
portion test for statistical significance in SAS v9.2. * Correspondence: shmorris@ucsd.edu
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There were 15 paired samples from HIV-infected indivi-
duals with confirmed NHL according to the ACSR data-
base. Cases of HIV-related NHL were mainly male
(93%) with median age of 47 (Table 1) and CD4 count
≤ 200 cells/ml in 9 (60%) cases. The median CD4 count
was 148 (range 5-1056) and the median log10 viral load
was 4.54 log copies/ml (range 3.32-5.88). Trofile assays
were performed on all samples but 6 of the samples
failed to culture and were non-reportable. Only one
reportable tropism had DM tropism (11.1%, 95% Exact
confidence interval 0.3-48.2%) and eight were CCR5
(88.9%, 95% Exact confidence interval (CI) 68.3-100%).
Based on an expected estimate of 50% CCR5 use in late
stage HIV-infected individuals the proportion of CCR5
tropism in the NHL samples was higher that expected
((P = 0.04). Tropism reportable cases had CD4 counts
with median of 148 cells/ml (range 5-821). Those with
reportable tropism did not differ in CD4 and viral load
to those without a reportable tropism (Wilcoxon two
sample t approximation p=0.39 and p=0.95). All
PBMC samples were testing for the SDF polymorphism
and four were heterozygous for the SDF1-3’A allele
(26.7%, 95% CI 7.8-55.1). This rate of SDF1-3’Aw a sn o
greater than expected in the general population based
on one sided binomial proportion test against a base
proportion of 21% (P = 0.39). Of the samples that had
reportable tropism there were three (33.3%) with SDF-
3’A heterozygosity. The one DM tropism was a SDF-3’A
heterozygote compared to 25% of CCR5 tropism.
Discussion
This is the first data that described the viral co-receptor
tropism in HIV-infected subjects with NHL. The finding
of only one of nine subjects had CXCR4 co-receptor
usage using the most sensitive assay was lower than
would have been expected and suggests a preponder-
ance of CCR5 use in the NHL subjects. In our cases,
SDF1-3’A was not significantly higher than the expected
population levels. Although SD1-3’A was found with the
only CXCR4 tropism, there was not enough outcomes
to verify an association. Contrary to our initial hypoth-
esis, our finding suggests, if there exists a relationship of
NHL with HIV co-receptor, it will be with persistent
CCR5 usage, but further studies are needed to validate
this association.
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